Home About us Contact
|
Home About us Contact | ||
|
|
||
Common Underlying Mechanism (common + underlying_mechanism)
Selected AbstractsMicrovasculitis In Non-Diabetic Lumbosacral Radiculoplexus Neuropathy (LSRPN): Similarity To The Diabetic Variety (DLSRPN)JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, Issue 1 2001Pjb Dyck Diabetic lumbosacral radiculoplexus neuropathy (DLSRPN) has been shown to be due to ischemic injury from microvasculitis. The present study tests whether ischemic injury and microvasculitis are the pathologic cause of non-diabetic lumbosacral radiculoplexus neuropathy (LSRPN), and whether the pathologic alterations are different between LSRPN and DLSRPN. We studied distal cutaneous nerve biopsies of 47 patients with LSRPN and compared findings with those of 14 age-matched healthy controls and 33 DLSRPN patients. In both disease conditions, we found evidence of ischemic injury (multifocal fiber degeneration and loss, perineurial degeneration and scarring, characteristic fiber alterations, neovascularization, and injury neuroma) that we attribute to microvasculitis (mural and perivascular mononuclear inflammation of microvessels, inflammatory separation, fragmentation and destruction of mural smooth muscle, and previous microscopic bleeding [hemosiderin]). Teased nerve fibers in LSRPN showed significantly increased frequencies of axonal degeneration, segmental demyelination, and empty nerve strands. The segmental demyelination appeared to be clustered on fibers with axonal dystrophy. The nerves with abnormal frequencies of demyelination were significantly associated with nerves showing multifocal fiber loss. We reached the following conclusions: 1) LSRPN is a serious condition with much morbidity that mirrors DLSRPN. 2) Ischemic injury from microvasculitis appears to be the cause of LSRPN. 3) Axonal degeneration and segmental demyelination appear to be linked and due to ischemia. 4) The pathologic alterations in LSRPN and DLSRPN are indistinguishable, raising the question whether these 2 conditions have a common underlying mechanism, and whether diabetes mellitus contributes to the pathology or is a risk factor in DLSRPN. 5) Both LSRPN and DLSRPN are potentially treatable conditions. [source] The Role of Glia and the Immune System in the Development and Maintenance of Neuropathic PainPAIN PRACTICE, Issue 3 2010Ricardo Vallejo MD Abstract Neuropathic pain refers to a variety of chronic pain conditions with differing underlying pathophysiologic mechanisms and origins. Recent studies indicate a communication between the immune system and the nervous system. A common underlying mechanism of neuropathic pain is the presence of inflammation at the site of the damaged or affected nerve(s). This inflammatory response initiates a cascade of events resulting in the concentration and activation of innate immune cells at the site of tissue injury. The release of immunoactive substances such as cytokines, neurotrophic factors, and chemokines initiate local actions and can result in a more generalized immune response. The resultant neuroinflammatory environment can cause activation of glial cells located in the spinal cord and the brain, which appear to play a prominent role in nociception. Glial cells, also known as neuroglia, are nonconducting cells that modulate neurotransmission at the synaptic level. Glial cells can be subdivided into two primary categories: microglia and macroglia, which include astrocytes and oligodendrocytes. Astrocytes and microglia are known to play a role in the development, spread, and potentiation of neuropathic pain. Following peripheral nociceptive activation via nerve injury, microglia become activated and release pro-inflammatory cytokines such as tumor necrosis factor-,, interleukin-1,, and interleukin-6, thereby initiating the pain process. Microglia propagate the neuroinflammation by recruiting other microglia and eventually activating nearby astrocytes, which prolongs the inflammatory state and leads to a chronic neuropathic pain condition. Our review focuses on the role of glia and the immune system in the development and maintenance of neuropathic pain. [source] Arylazoamidoximes and Related Compounds as NO-modulatorsARCHIV DER PHARMAZIE, Issue 1 2010Alexander Schröder Abstract Three amidinoarylhydrazines 1, three arylazoamidines 2, and nine arylazoamidoximes 3 have been synthesized and investigated for their potential to function as nitric oxide (NO) modulators. In-vitro studies demonstrated that 2 and 3 inhibited platelet aggregation (2c, IC50 = 3 ,M) which could also be shown in vivo by inhibition of thrombus formation in arterioles (3a, 22%). Moreover, for all compounds antihypertensive effects were examined in vivo with SHR rats, with 2a being the most potent candidate by lowering blood pressure by 19%. However, no common underlying mechanism of action could be shown. Some of these compounds released HNO non-enzymatically. Incubations with NO synthase isoforms (NOSs) revealed, that compounds 1 to 3 were weak substrates for NOSs but arylazoamidoximes 3 remarkably elevated the NOSs activity in the presence of L -arginine (3h, up to fivefold). In addition, we examined effects on arginase and dimethylarginine dimethylaminohydrolase (DDAH), two further enzymes involved in the complex regulation of NO biosynthesis, to elucidate whether the observed in-vivo effects can be traced back to their modulation. Furthermore, the metabolic fate of arylazoamidoximes 3 was addressed by investigation of a possible N -reductive biotransformation. In summary, novel NO-modulating compound classes are presented, among which arylazoamidoximes 3 are potent activators of NOS isoforms, and arylazoamidines 2 exert in-vivo effects by unknown mechanisms. [source] Effects of the History of Conduct Disorder on the Iowa Gambling TasksALCOHOLISM, Issue 3 2006Yang Tae Kim Background: Recent research conducted with the Iowa Gambling Task (GT) suggests decision-making impairments in substance dependence, as well as behavior disorders such as conduct disorder and attention-deficit/hyperactivity disorder. However, little is known about the past history of conduct disorder on decision making. The purpose of this study was to test the possible effect of past history of conduct disorder on GT performance and how this factor could contribute to the performance on GT in alcohol-dependent patients. Methods: Four subject groups were tested: (1) alcohol-dependent patients with (n=28) and (2) alcohol-dependent patients without (n=28), a history of conduct disorder and (3) normal controls with (n=10) and (4) normal controls without (n=30) a history of conduct disorder. Demographic and alcohol-related variables were evaluated, and a decision-making task, "Iowa GT," both original and variant version, were applied. Results: As a whole, normal controls with a history of conduct disorder and alcohol-dependent patients with or without a history of conduct disorder show impaired decision making because of hypersensitivity to reward and hyposensitivity to punishment. However, no significant differences were noted between alcohol-dependent patients either with or without a history of conduct disorder on gambling performance. Conclusions: These results indicate that the history of conduct disorder may contribute to impaired decision making on GT. Furthermore, this kind of decision-making pattern may represent one of common underlying mechanisms in both conduct disorder and alcohol dependence. [source] | ||||||||||